Business Context and Reporting Period
Company: ZIMMER BIOMET HOLDINGS, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: January 28, 2016
Reporting Period: Quarter and year ended December 31, 2015
This filing serves as a notification that the company has reported its results of operations for the specified period. The detailed financial data is contained in the attached earnings release (Exhibit 99.1), which is incorporated by reference.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It only describes the methodology for presenting these metrics in the attached exhibit:
- Sales Growth: Presented on reported (GAAP), pro forma reported, and adjusted pro forma constant currency bases.
- Non-GAAP Measures: Includes adjusted net earnings and adjusted diluted EPS, which exclude inventory step-up, merger-related expenses, intangible asset amortization, and special items.
- Special Items: Defined to include acquisition/integration costs, asset impairments, employee termination benefits, and restructuring charges.
Material Changes
The filing text does not provide specific quantitative comparisons to prior periods. It notes that the company utilizes pro forma adjustments to reflect the inclusion of Biomet revenue on a GAAP basis and excludes the impact of previously announced divestiture remedies to facilitate meaningful period-to-period comparisons.
Guidance, Outlook, and Management Commentary
Management Commentary: Management utilizes the described non-GAAP measures internally to evaluate business performance, identify operating trends masked by one-time items, and perform trend analysis. These measures are also used as performance metrics in incentive compensation programs.
Guidance and Risks: The text mentions that projected adjusted diluted EPS is included in the attached earnings release but does not state the specific figures here. No specific risks or contingencies are detailed in the body of this 8-K summary, other than the standard disclaimer regarding the materiality of the information.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, earnings, and cash flow figures.
- Examine the reconciliation tables in the earnings release to understand the difference between GAAP and non-GAAP measures.
- Verify the specific impact of the Biomet merger integration costs and divestiture remedies on the reported numbers.
- Check the "projected adjusted diluted EPS" figures for future guidance.